文献速递其他结缔组织病

抗制瘤素M单克隆抗体治疗系统性硬化症的随机2期研究:生物学与临床启示

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

这项多中心、随机、双盲、安慰剂对照2期研究纳入35例活动性弥漫性皮肤型系统性硬化症(dcSSc)患者,按3:1随机接受GSK2330811(抗制瘤素M单克隆抗体)100 mg、300 mg或安慰剂皮下注射每两周一次共12周。主要终点为安全性;未证实炎症或纤维化生物标志物的机制证明,各疗效终点与安慰剂无有意义的差异,300 mg组安全性和耐受性不佳,出现与血红蛋白和血小板计数下降相关的靶点依赖性不良事件。作者认为抑制制瘤素M可能不是系统性硬化症的有效治疗策略。

要点

  • 35例活动性dcSSc患者随机接受GSK2330811 100 mg(n=3)、300 mg(n=24)或安慰剂(n=8)皮下注射每两周一次共12周。
  • 未证实GSK2330811对炎症或纤维化生物标志物的协同机制效应,各疗效终点与安慰剂无有意义的差异。
  • 300 mg组安全性和耐受性不佳,出现与血红蛋白和血小板计数下降相关的靶点依赖性不良事件,100 mg组和安慰剂组未观察到。

核心结论

  • 尽管采用了稳健且新颖的实验医学方法并有靶点结合的證據,GSK2330811预期的系统性硬化症相关生物学效应与安慰剂无差异且安全性不佳,提示抑制制瘤素M可能不是系统性硬化症的有效治疗策略。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2期研究,纳入35例年龄≥18岁的活动性弥漫性皮肤型系统性硬化症(dcSSc)患者。
  • 参与者按3:1随机(GSK2330811:安慰剂)进入两个序贯队列之一,接受GSK2330811(队列1:100 mg;队列2:300 mg)或安慰剂皮下注射每两周一次共12周。
  • 主要终点为安全性;采集血液和皮肤活检样本以探索对炎症和纤维化的机制效应;临床疗效为探索性终点。

主要发现

  • 35例参与者被随机分配至安慰剂(n=8)、GSK2330811 100 mg(n=3)或GSK2330811 300 mg(n=24)。
  • 通过炎症或纤维化生物标志物的协同效应衡量的机制证明,在GSK2330811治疗后未得到证实。
  • GSK2330811与安慰剂在任何疗效终点上均无有意义的差异。
  • 300 mg组GSK2330811的安全性和耐受性不佳,出现与血红蛋白和血小板计数下降相关的靶点依赖性、剂量依赖性不良事件,100 mg组或安慰剂组未观察到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process. METHODS: This multicentre, randomized, double-blind, placebo-controlled study enrolled participants ≥18 years of age with active dcSSc. Participants were randomized 3:1 (GSK2330811:placebo) in one of two sequential cohorts to receive GSK2330811 (cohort 1: 100 mg; cohort 2: 300 mg) or placebo s.c. every other week for 12 weeks. The primary endpoint was safety; blood and skin biopsy samples were collected to explore mechanistic effects on inflammation and fibrosis. Clinical efficacy was an exploratory endpoint. RESULTS: Thirty-five participants were randomized to placebo (n = 8), GSK2330811 100 mg (n = 3) or GSK2330811 300 mg (n = 24). Proof of mechanism, measured by coordinate effects on biomarkers of inflammation or fibrosis, was not demonstrated following GSK2330811 treatment. There were no meaningful differences between GSK2330811 and placebo for any efficacy endpoints. The safety and tolerability of GSK2330811 were not favourable in the 300 mg group, with on-target, dose-dependent adverse events related to decreases in haemoglobin and platelet count that were not observed in the 100 mg or placebo groups. CONCLUSION: Despite a robust and novel experimental medicine approach and evidence of target engagement, anticipated SSc-related biologic effects of GSK2330811 were not different from placebo and safety was unfavourable, suggesting OSM inhibition may not be a useful therapeutic strategy in SSc. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT03041025; EudraCT, 2016-003417-95.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Denton CP, Del Galdo F, Khanna D, et al. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology (Oxford). 2022. PMID: 35583273. doi:10.1093/rheumatology/keac300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。